Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study).
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
15 Feb 2024
15 Feb 2024
Historique:
received:
01
07
2023
accepted:
22
12
2023
medline:
16
2
2024
pubmed:
16
2
2024
entrez:
15
2
2024
Statut:
epublish
Résumé
Persons with opioid use disorders who inject drugs (PWID) in the United States (US) face multiple and intertwining health risks. These include interference with consistent access, linkage, and retention to health care including medication for opioid use disorder (MOUD), HIV prevention using pre-exposure prophylaxis (PrEP), and testing and treatment for sexually transmitted infections (STIs). Most services, when available, including those that address substance misuse, HIV prevention, and STIs, are often provided in multiple locations that may be difficult to access, which further challenges sustained health for PWID. HPTN 094 (INTEGRA) is a study designed to test the efficacy of an integrated, "whole-person" strategy that provides integrated HIV prevention including antiretroviral therapy (ART), PrEP, MOUD, and STI testing and treatment from a mobile health delivery unit ("mobile unit") with peer navigation compared to peer navigation alone to access these services at brick and mortar locations. HPTN 094 (INTEGRA) is a two-arm, randomized controlled trial in 5 US cities where approximately 400 PWID without HIV are assigned either to an experimental condition that delivers 26 weeks of "one-stop" integrated health services combined with peer navigation and delivered in a mobile unit or to an active control condition using peer navigation only for 26 weeks to the same set of services delivered in community settings. The primary outcomes include being alive and retained in MOUD and PrEP at 26 weeks post-randomization. Secondary outcomes measure the durability of intervention effects at 52 weeks following randomization. This trial responds to a need for evidence on using a "whole-person" strategy for delivering integrated HIV prevention and substance use treatment, while testing the use of a mobile unit that meets out-of-treatment PWID wherever they might be and links them to care systems and/or harm reduction services. Findings will be important in guiding policy for engaging PWID in HIV prevention or care, substance use treatment, and STI testing and treatment by addressing the intertwined epidemics of addiction and HIV among those who have many physical and geographic barriers to access care. ClinicalTrials.gov NCT04804072 . Registered on 18 March 2021.
Sections du résumé
BACKGROUND
BACKGROUND
Persons with opioid use disorders who inject drugs (PWID) in the United States (US) face multiple and intertwining health risks. These include interference with consistent access, linkage, and retention to health care including medication for opioid use disorder (MOUD), HIV prevention using pre-exposure prophylaxis (PrEP), and testing and treatment for sexually transmitted infections (STIs). Most services, when available, including those that address substance misuse, HIV prevention, and STIs, are often provided in multiple locations that may be difficult to access, which further challenges sustained health for PWID. HPTN 094 (INTEGRA) is a study designed to test the efficacy of an integrated, "whole-person" strategy that provides integrated HIV prevention including antiretroviral therapy (ART), PrEP, MOUD, and STI testing and treatment from a mobile health delivery unit ("mobile unit") with peer navigation compared to peer navigation alone to access these services at brick and mortar locations.
METHODS
METHODS
HPTN 094 (INTEGRA) is a two-arm, randomized controlled trial in 5 US cities where approximately 400 PWID without HIV are assigned either to an experimental condition that delivers 26 weeks of "one-stop" integrated health services combined with peer navigation and delivered in a mobile unit or to an active control condition using peer navigation only for 26 weeks to the same set of services delivered in community settings. The primary outcomes include being alive and retained in MOUD and PrEP at 26 weeks post-randomization. Secondary outcomes measure the durability of intervention effects at 52 weeks following randomization.
DISCUSSION
CONCLUSIONS
This trial responds to a need for evidence on using a "whole-person" strategy for delivering integrated HIV prevention and substance use treatment, while testing the use of a mobile unit that meets out-of-treatment PWID wherever they might be and links them to care systems and/or harm reduction services. Findings will be important in guiding policy for engaging PWID in HIV prevention or care, substance use treatment, and STI testing and treatment by addressing the intertwined epidemics of addiction and HIV among those who have many physical and geographic barriers to access care.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04804072 . Registered on 18 March 2021.
Identifiants
pubmed: 38360750
doi: 10.1186/s13063-023-07899-5
pii: 10.1186/s13063-023-07899-5
doi:
Banques de données
ClinicalTrials.gov
['NCT04804072']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
124Subventions
Organisme : National Institute of Allergy and Infectious Diseases
ID : UM1AI068619-15
Organisme : National Institute of Allergy and Infectious Diseases
ID : UM1AI068617-15
Organisme : National Institute of Allergy and Infectious Diseases
ID : UM1AI068613-15
Informations de copyright
© 2024. The Author(s).
Références
Ahmad FB, Cisewski JA, Anderson RN. Provisional mortality data—United States, 2021. MMWR Morb Mortal Wkly Rep. 2022;71:597–600.
doi: 10.15585/mmwr.mm7117e1
pubmed: 35482572
pmcid: 9098238
Kariisa MDN, Kumar S, et al. Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics—25 states and the District of Columbia, 2019–2020. MMWR Morb Mortal Wkly Rep. 2022;71:940–7.
doi: 10.15585/mmwr.mm7129e2
pubmed: 35862289
pmcid: 9310633
Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344–50.
doi: 10.1097/YCO.0000000000000717
pubmed: 33965972
pmcid: 8154745
Spetz J, Hailer L, Gay C, Tierney M, Schmidt L, Phoenix B, et al. Changes in US clinician waivers to prescribe buprenorphine management for opioid use disorder during the COVID-19 pandemic and after relaxation of training requirements. JAMA Netw Open. 2022;5(5):e225996.
doi: 10.1001/jamanetworkopen.2022.5996
pubmed: 35552728
pmcid: 9099425
Amram O, Amiri S, Panwala V, Lutz R, Joudrey PJ, Socias E. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. Am J Drug Alcohol Abuse. 2021;47(6):722–9.
doi: 10.1080/00952990.2021.1979991
pubmed: 34670453
Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–6.
doi: 10.1056/NEJMp1402780
pubmed: 24758595
Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review prevention and treatment of opioid misuse and addiction prevention and treatment of opioid misuse and addiction. JAMA Psychiatry. 2019;76(2):208–16.
doi: 10.1001/jamapsychiatry.2018.3126
pubmed: 30516809
Mauro PM, Gutkind S, Annunziato EM, Samples H. Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019. JAMA Netw Open. 2022;5(3):e223821.
doi: 10.1001/jamanetworkopen.2022.3821
pubmed: 35319762
pmcid: 8943638
Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerdá M. Has the treatment gap for opioid use disorder narrowed in the U.S.?: a yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786.
doi: 10.1016/j.drugpo.2022.103786
pubmed: 35934583
Dong H, Stringfellow EJ, Russell WA, Jalali MS. Racial and ethnic disparities in buprenorphine treatment duration in the US. JAMA Psychiatry. 2023;80(1):93–5. https://doi.org/10.1001/jamapsychiatry.2022.3673 .
National Academies of Sciences E, and Medicine. Opportunities to improve opioid use disorder and infectious disease services: integrating responses to a dual epidemic. Washington DC: The National Academies Press; 2020.
Harvey L, Boudreau J, Sliwinski SK, Strymish J, Gifford AL, Hyde J, et al. Six moments of infection prevention in injection drug use: an educational toolkit for clinicians. Open Forum Infect Dis. 2022;9(2):ofab631.
doi: 10.1093/ofid/ofab631
pubmed: 35097153
pmcid: 8794071
Handanagic S, Finlayson T, Burnett JC, Broz D, Wejnert C. HIV infection and HIV-associated behaviors among persons who inject drugs - 23 metropolitan statistical areas, United States, 2018. MMWR Morb Mortal Wkly Rep. 2021;70(42):1459–65.
doi: 10.15585/mmwr.mm7042a1
pubmed: 34673746
pmcid: 9361835
Rosenberg ES, Rosenthal EM, Hall EW, Barker L, Hofmeister MG, Sullivan PS, et al. Prevalence of hepatitis C virus infection in US states and the district of Columbia, 2013 to 2016. JAMA Netw Open. 2018;1(8):e186371.
doi: 10.1001/jamanetworkopen.2018.6371
pubmed: 30646319
pmcid: 6324373
Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny I, Razavi H, Vickerman P. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797–808.
doi: 10.1016/S1473-3099(15)00485-5
pubmed: 26922272
Williams LD, Ibragimov U, Tempalski B, Stall R, Satcher Johnson A, Wang G, et al. Trends over time in HIV prevalence among people who inject drugs in 89 large US metropolitan statistical areas, 1992–2013. Ann Epidemiol. 2020;45:12–23.
doi: 10.1016/j.annepidem.2020.03.011
pubmed: 32439148
pmcid: 7430257
Des Jarlais DC, Sypsa V, Feelemyer J, Abagiu AO, Arendt V, Broz D, et al. HIV outbreaks among people who inject drugs in Europe, North America, and Israel. Lancet HIV. 2020;7(6):e434–42.
doi: 10.1016/S2352-3018(20)30082-5
pubmed: 32504576
Strathdee SA, Kuo I, El-Bassel N, Hodder S, Smith LR, Springer SA. Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose. AIDS. 2020;34(14):1997–2005.
doi: 10.1097/QAD.0000000000002673
pubmed: 32826391
Miller WC, Hoffman IF, Hanscom BS, Ha TV, Dumchev K, Djoerban Z, et al. A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Lancet. 2018;392(10149):747–59.
doi: 10.1016/S0140-6736(18)31487-9
pubmed: 30191830
pmcid: 6299325
Bartholomew TS, Andraka-Cristou B, Totaram RK, Harris S, Doblecki-Lewis S, Ostrer L, et al. “We want everything in a one-stop shop”: acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs. Harm Reduct J. 2022;19(1):133.
doi: 10.1186/s12954-022-00721-6
pubmed: 36463183
pmcid: 9719627
Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375(3):229–39.
doi: 10.1056/NEJMoa1515195
pubmed: 27468059
Golden MR, Lechtenberg R, Glick SN, Dombrowski J, Duchin J, Reuer JR, et al. Outbreak of human immunodeficiency virus infection among heterosexual persons who are living homeless and inject drugs - Seattle, Washington, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(15):344–9.
doi: 10.15585/mmwr.mm6815a2
pubmed: 30998671
pmcid: 6476056
Cranston K, Alpren C, John B, Dawson E, Roosevelt K, Burrage A. Notes from the field: HIV diagnoses among persons who inject drugs - northeastern Massachusetts, 2015–2018. MMWR Morb Mortal Wkly Rep. 2019;68(10):253–4.
doi: 10.15585/mmwr.mm6810a6
pubmed: 30870405
pmcid: 6421964
Centers for Disease Control and Prevention (CDC). HIV surveillance report, 2014. 2015.
(CDC) CfDCaP. HIV surveillance report, 2019. 2021. p. 32.
Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through September 2022; and preexposure prophylaxis (PrEP) data reported through June 2022. 2022. Available from: https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/ .
Streed CG Jr, Morgan JR, Gai MJ, Larochelle MR, Paasche-Orlow MK, Taylor JL. Prevalence of HIV preexposure prophylaxis prescribing among persons with commercial insurance and likely injection drug use. JAMA Netw Open. 2022;5(7):e2221346.
doi: 10.1001/jamanetworkopen.2022.21346
pubmed: 35819784
pmcid: 9277489
El-Bassel N, Marotta PL, Gilbert L, Wu E, Springer S, Goddard-Eckrich D, et al. Integrating treatment for opioid use disorders and HIV services into primary care: solutions for the 21st century. In: Crosby RA, DiClemente RJ, (eds), Structural interventions for HIV prevention: optimizing strategies for reducing new infections and improving care. New York: Oxford Academic; 2018. https://doi.org/10.1093/oso/9780190675486.003.0008 .
Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, et al. Developing an opioid use disorder treatment cascade: a review of quality measures. J Subst Abuse Treat. 2018;91:57–68.
doi: 10.1016/j.jsat.2018.06.001
pubmed: 29910015
pmcid: 6039975
Primm B. Overview of the Office for Treatment Improvement and its philosophy. J Psychoactive Drugs. 1991;23(2):113–4.
doi: 10.1080/02791072.1991.10472229
pubmed: 1765886
Centers for Disease Control and Prevention (CDC). HIV surveillance report, 2020. Atlanta; 2020 [11-15-2022]. Available from: https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html .
Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–6.
doi: 10.1016/j.jsat.2017.07.001
pubmed: 28733097
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). 2013. https://doi.org/10.1176/appi.books.9780890425596 .
Forder A. Social work and system theory. Br J Soc Work. 1976;6(1):23–42.
Ryan RM, Deci EL. Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. Am Psychol. 2000;55:68–78.
doi: 10.1037/0003-066X.55.1.68
pubmed: 11392867
Perkins DD, Zimmerman MA. Empowerment theory, research, and application. Am J Community Psychol. 1995;23(5):569–79.
doi: 10.1007/BF02506982
pubmed: 8851340
Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–7.
doi: 10.1007/s11606-012-2077-6
pubmed: 22618581
pmcid: 3445676
Vaux A. Social support: theory, research, and intervention. Praeger Publishers; 1988. p. xiv, 346-xiv.
Feldstein AC, Glasgow RE. A Practical, Robust Implementation and Sustainability Model (PRISM) for integrating research findings into practice. Jt Comm J Qual Patient Saf. 2008;34(4):228–43.
pubmed: 18468362
Miller CJ, Barnett ML, Baumann AA, Gutner CA, Wiltsey-Stirman S. The FRAME-IS: a framework for documenting modifications to implementation strategies in healthcare. Implement Sci. 2021;16(1):36.
doi: 10.1186/s13012-021-01105-3
pubmed: 33827716
pmcid: 8024675
U.S. Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS). Table for grading the severity of adult and pediatric adverse events, corrected version 2.1. 2017. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf . Cited 12-10-2023.
ICMJE. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. 2023. [updated May 202311/14/2023]. Available from: https://www.icmje.org/icmje-recommendations.pdf .
Iyengar S, Kravietz A, Bartholomew TS, Forrest D, Tookes HE. Baseline differences in characteristics and risk behaviors among people who inject drugs by syringe exchange program modality: an analysis of the Miami IDEA syringe exchange. Harm Reduct J. 2019;16(1):7.
doi: 10.1186/s12954-019-0280-z
pubmed: 30674334
pmcid: 6343273
Allen ST, Ruiz MS, Jones J. Assessing syringe exchange program access among persons who inject drugs (PWID) in the district of Columbia. J Urban Health. 2016;93(1):131–40.
doi: 10.1007/s11524-015-0018-5
pubmed: 26786782
pmcid: 4794462
Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355.
doi: 10.1371/journal.pone.0081355
pubmed: 24367482
pmcid: 3867319
Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293–9.
doi: 10.1016/S0140-6736(08)61113-7
Metzger DS, Woody GE, McLellan AT, O’Brien CP, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr (1988). 1993;6(9):1049–56.
pubmed: 8340896